Epirubicin: Biological Properties, Analytical Methods, and Drug Delivery Nanosystems

被引:12
作者
Luiz, Marcela Tavares [1 ]
Dutra, Jessyca Aparecida Paes [2 ]
Di Filippo, Leonardo Delello [2 ]
Junior, Alberto Gomes Tavares [2 ]
Tofani, Larissa Bueno [1 ]
Marchetti, Juliana Maldonado [1 ]
Chorilli, Marlus [2 ]
机构
[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ribeirao Preto, Brazil
[2] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP, Brazil
关键词
Chromatography; fluorimetry; nanomedicine; nanoparticles; spectroscopy; SOLID LIPID NANOPARTICLES; IN-VITRO; HUMAN PLASMA; POLY(BUTYL CYANOACRYLATE); CHROMATOGRAPHY METHOD; ANTINEOPLASTIC DRUGS; FACTOR ANTIBODY; PHARMACOKINETICS; CHEMOTHERAPY; METABOLITE;
D O I
10.1080/10408347.2021.2007469
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Epirubicin (EPI) is a chemotherapeutic agent belonging to the anthracycline drug class indicated for treating several tumors. It acts by suppressing the DNA and RNA synthesis by intercalating between their base pair. However, several side effects are associated with this therapy, including cardiotoxicity and myelosuppression. Therefore, EPI delivery in nanosystems has been an interesting strategy to overcome these limitations and improve the safety and efficacy of EPI. Thus, analytical methods have been used to understand and characterize these nanosystems, including spectrophotometric, spectrofluorimetric, and chromatography. Spectrophotometric and spectrofluorimetric methods have been used to quantify EPI in less complex matrices due to their efficiency, low cost, and green chemistry character. By contrast, high-performance liquid chromatography is a suitable method for detecting EPI in more complex matrices (e.g., plasm and urine) owing to its high sensitivity. This review summarizes physicochemical and pharmacokinetic properties of EPI, its application in drug delivery nanosystems, and the analytical methods employed in its quantification in different matrices, including blood, plasm, urine, and drug delivery nanosystems.
引用
收藏
页码:1080 / 1093
页数:14
相关论文
共 96 条
  • [1] Structure and function of the blood-brain barrier
    Abbott, N. Joan
    Patabendige, Adjanie A. K.
    Dolman, Diana E. M.
    Yusof, Siti R.
    Begley, David J.
    [J]. NEUROBIOLOGY OF DISEASE, 2010, 37 (01) : 13 - 25
  • [2] Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations
    Alavi, Mehran
    Varma, Rajender S.
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 164 : 2197 - 2203
  • [3] Development and characterization of folic acid-functionalized apoferritin as a delivery vehicle for epirubicin against MCF-7 breast cancer cells
    Alqaraghuli, Hasanain Gomhor J.
    Kashanian, Soheila
    Rafipour, Ronak
    Mahdavian, Elahe
    Mansouri, Kamran
    [J]. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 : S847 - S854
  • [4] Albumin-stabilized epirubicin nanocarriers of core-shell type based on poly(butyl cyanoacrylate) and poly(styrene-co-maleic acid)
    Angelova, Nadezhda
    Yordanov, Georgi
    [J]. COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2015, 487 : 232 - 239
  • [5] Nanoparticles of poly(styrene-co-maleic acid) as colloidal carriers for the anticancer drug epirubicin
    Angelova, Nadezhda
    Yordanov, Georgi
    [J]. COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2014, 452 : 73 - 81
  • [6] Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells
    Ansari, Legha
    Derakhshi, Mansooreh
    Bagheri, Elnaz
    Shahtahmassebi, Nasser
    Malaekeh-Nikouei, Bizhan
    [J]. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2020, 25 (05) : 601 - 609
  • [7] Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies
    Ansari, Legha
    Jaafari, Mahmoud Reza
    Bastami, Tahereh Rohani
    Malaekeh-Nikouei, Bizhan
    [J]. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 : 594 - 606
  • [8] Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study
    Banda, Jagadeesh
    Lakshmanan, Ramalingam
    Katepalli, Ramesh Babu
    Venati, Uday Kumar Reddy
    Koppula, Ramesh
    Prasad, V. V. S. Shiva
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2016, 1008 : 1 - 10
  • [9] Barbosa FDS., 2017, Drug Anal Res Porto Alegre RS, V1, P24, DOI [DOI 10.22456/2527-2616.79219, 10.22456/2527-2616.79219]
  • [10] Advances and new technologies applied in controlled drug delivery system
    Bassyouni, Fatma
    ElHalwany, Noha
    Rehim, Mohamed Abdel
    Neyfeh, Munir
    [J]. RESEARCH ON CHEMICAL INTERMEDIATES, 2015, 41 (04) : 2165 - 2200